Skip to content
Virpax Pharmaceuticals Logo
  • HOME
  • ABOUT
  • PRODUCTS
    • PORTFOLIO
    • GLOBAL SUBLICENSING
    • BEHIND THE SCIENCE
    • PUBLICATIONS
  • TEAM
  • INVESTORS
  • RECENT MEDIA
  • CONTACT
  • HOME
  • ABOUT
  • PRODUCTS
    • PORTFOLIO
    • GLOBAL SUBLICENSING
    • BEHIND THE SCIENCE
    • PUBLICATIONS
  • TEAM
  • INVESTORS
  • RECENT MEDIA
  • CONTACT
Virpax Pharmaceuticals Logo
  • HOME
  • ABOUT
  • PRODUCTS
    • PORTFOLIO
    • GLOBAL SUBLICENSING
    • BEHIND THE SCIENCE
    • PUBLICATIONS
  • TEAM
  • INVESTORS
  • RECENT MEDIA
  • CONTACT
Virpax Pharmaceuticals Enters into CRADA with the National Advisory Neurological Disorders and Stroke Council

Jun 26, 2023

Virpax Pharmaceuticals Enters into CRADA with the National Advisory Neurological Disorders and Stroke Council

admin2023-06-27T20:47:40-04:00June 26th, 2023|Media|
Virpax Pharma new pain management

NASDAQ: VRPX

Corporate Headquarters
1055 Westlakes Drive, Suite 300
Berwyn, PA 19312

Phone 610.727.4597
Email info@virpaxpharma.com

Virpax Pharma new pain management

NASDAQ: VRPX

Corporate Headquarters
1055 Westlakes Drive, Suite 300
Berwyn, PA 19312

Phone 610.727.4597
Email info@virpaxpharma.com

  • HOME
  • ABOUT
  • PRODUCTS
  • TEAM
  • INVESTORS
  • RECENT MEDIA
  • CONTACT
  • GLOBAL SUBLICENSING
  • BEHIND THE SCIENCE
  • PUBLICATIONS

© Virpax® Pharmaceuticals. All Rights Reserved.

© Virpax® Pharmaceuticals. All Rights Reserved.

Follow @VirpaxPharma
Follow @VirpaxPharma
Page load link
Go to Top